Summary: Molbio Diagnostics, a Goa-based point-of-care molecular diagnostics company, opens its IPO on August 10, 2026, at a price band of ₹768–₹807 per share. The ₹939.7 crore bookbuilding issue combines a ₹200 crore fresh issue with a ₹739.7 crore offer for sale, closes on August 12, and lists tentatively on August 17 on BSE and NSE.
Introduction
Best known for its Truenat platform, a portable PCR-based diagnostic system built for resource-limited settings, Molbio has built a diagnostics business spanning over 30 diseases. This is the company's first move into public markets after 26 years as a private business.
Molbio Diagnostics IPO: Key highlights
| Detail | Information |
| Price band | ₹768 to ₹807 per share |
| Face value | ₹1 per share |
| Lot size | 18 shares |
| Minimum investment (retail) | ₹14,526 |
| Employee discount | ₹76 per share |
| Issue size | ₹939.7 crore |
| Fresh issue | ₹200 crore |
| Offer for sale | ₹739.7 crore |
| Listing at | BSE, NSE |
| Registrar | Kfin Technologies |
Molbio Diagnostics IPO dates & timeline
| Event | Date |
| IPO opens | Monday, August 10, 2026 |
| IPO closes | Wednesday, August 12, 2026 |
| Basis of allotment | Thursday, August 13, 2026 |
| Refund initiation | Friday, August 14, 2026 |
| Credit of shares to demat | Friday, August 14, 2026 |
| Listing date | Monday, August 17, 2026 |
Three days of bidding, then a short run into allotment and listing about a week out. Fairly standard pacing for a mainboard issue this size.
Molbio Diagnostics IPO price band, lot size & minimum investment
Shares carry a face value of ₹1 and sit in the ₹768–₹807 band. Retail investors and eligible employees can bid at the cut-off price, but small and big HNI categories cannot.
| Application | Lots | Shares | Amount |
| Retail (min) | 1 | 18 | ₹14,526 |
| Retail (max) | 13 | 234 | ₹1,88,838 |
| Small HNI (min) | 14 | 252 | ₹2,03,364 |
| Small HNI (max) | 68 | 1,224 | ₹9,87,768 |
| Big HNI (min) | 69 | 1,242 | ₹10,02,294 |
Employees bidding within their reserved quota get the ₹76 per share discount on top of cut-off pricing.
Molbio Diagnostics IPO issue size & offer structure
The total issue works out to a little over 1.16 crore shares, aggregating up to ₹939.7 crore at the top of the price band.
| Component | Shares | Amount |
| Total issue size | 1,16,46,246 | ₹939.7 crore |
| Fresh issue | 24,80,246 | ₹200 crore |
| Offer for sale | 91,66,000 | ₹739.7 crore |
The OFS draws from a spread of sellers, promoters like Exxora Trading LLP and Chandrasekhar Bhaskaran Nair among them, alongside India Business Excellence Fund III and a handful of individual shareholders. Promoter holding sits at close to 46.65% pre-issue and drops to around 43% after, with public shareholding climbing to just under 57%.
Objectives of the IPO
Only the fresh issue money, ₹200 crore, reaches the company. The OFS portion goes straight to the selling shareholders instead. Of what is raised, the biggest chunk is going toward a new research and development facility, along with a Center of Excellence and connected office space. Another slice covers plant, machinery, and equipment across the company's Goa and Visakhapatnam units. What is left is kept for general corporate purposes.
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics works in point-of-care molecular diagnostics, covering research, development, manufacturing, and commercialisation of rapid diagnostic solutions for infectious and non-communicable diseases. Its core product is Truenat, a portable, battery-operated PCR-based diagnostics platform built for resource-limited settings. Where a conventional lab might take days, Truenat is designed to return results within an hour.
The testing portfolio covers more than 30 diseases across 43 diagnostic assays, including tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV among them, putting the company across some of the conditions most commonly tested for in public health work. Manufacturing runs out of two units in Goa and one in Visakhapatnam, with IPO proceeds earmarked to expand that further. A group of individual promoters lead the company alongside Exxora Trading LLP, and this listing marks its first step into public markets since it was founded.
Financial performance
Molbio's numbers have climbed steadily over the past three fiscal years.
| Metric | FY24 | FY25 | FY26 |
| Total income | ₹840.66 Cr | ₹1,027.94 Cr | ₹1,455.17 Cr |
| Profit after tax | ₹83.54 Cr | ₹138.58 Cr | ₹164.14 Cr |
| EBITDA | ₹185.09 Cr | ₹256.64 Cr | ₹328.24 Cr |
| Net worth | ₹807.94 Cr | ₹952.95 Cr | ₹1,144.68 Cr |
| Total borrowings | ₹174.58 Cr | ₹123.16 Cr | ₹412.64 Cr |
| Key ratio | FY25 | FY26 |
| ROE | 16.20% | 15.59% |
| ROCE | 20.98% | 17.55% |
| RoNW | 15.23% | 14.55% |
| EBITDA margin | 24.97% | 22.56% |
| Post-issue P/E | - | 56.67x |
Revenue and profit both grew well through FY26. Return ratios eased a bit compared to the year before, though, and borrowings rose alongside a broader expansion of the balance sheet. Margins softened slightly too, worth keeping an eye on as the company scales into new capacity.
Strengths of Molbio Diagnostics
- A proprietary platform in Truenat, built for resource-limited settings, a category where competition is comparatively thin.
- A broad testing portfolio spanning over 30 diseases, so the business does not hinge on any single test or condition.
- Steady revenue and profit growth across the past three fiscal years, with FY26 income up sharply.
- Manufacturing already running across three units in Goa and Visakhapatnam, giving a base to build additional capacity on.
- IPO money going toward R&D and manufacturing expansion rather than just debt repayment or shareholder payouts.
Risks investors should know
- Post-issue P/E of 56.67x is a rich multiple, and ROE and RoNW both eased slightly in FY26 against the year before.
- The offer for sale makes up the larger share of the issue, so most proceeds go to existing shareholders rather than the business.
- EBITDA margins softened year-on-year, worth watching alongside the company's capacity plans.
- Borrowings rose meaningfully in FY26, a shift from the two years before.
- Diagnostics demand can move with public health cycles, which may make revenue less predictable over time.
Should you track the Molbio Diagnostics IPO?
There is a case for keeping an eye on this one. Truenat gives Molbio a genuinely different position in point-of-care diagnostics, a space that matters across both infectious and non-communicable disease testing. Revenue growth through FY26 has been strong, and the fresh issue money is going toward real capacity and R&D expansion, not just tidying up the balance sheet.
The harder part is the price. Nearly 57 times post-issue earnings is not cheap, and margins, along with return ratios, both eased this year. The OFS-heavy structure means a large part of this listing benefits existing shareholders too. Whether the growth story is worth what is being asked comes down to how much confidence an investor has in Molbio holding its current pace.
Latest Molbio Diagnostics IPO subscription updates
- Bidding has not opened yet; subscription figures begin once the public issue window starts on August 10.
- QIB is capped at 50% of the net offer, while retail is guaranteed at least 35%. Both are worth tracking once the book opens.
- Employees applying within their reserved limit get the ₹76 per share discount along with cut-off pricing.
- Category-wise numbers update through the three-day bidding window, August 10 to August 12.
Conclusion
Molbio Diagnostics brings a genuinely different point-of-care diagnostics business to market at ₹768–₹807 a share, with bidding running August 10 to 12 and listing set for August 17. Growth through FY26 has been strong, but the rich valuation and softer margins are worth a closer look before deciding where this fits in a portfolio. The days ahead of bidding, and the listing itself, will show how the market ends up pricing that trade-off.
